BRCA1 Haplotype and Clinical Benefit of Trabectedin in Soft-Tissue Sarcoma Patients

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2014.624
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Trabectedin in the Treatment of Patients With Soft Tissue Sarcoma

Nowotwory
Cancer ResearchOncology
2018English

Trabectedin Plus Olaparib Has Activity in Patients With Soft-Tissue Sarcoma

Cancer Discovery
Oncology
2018English

Role of Trabectedin in the Treatment of Soft Tissue Sarcoma

OncoTargets and Therapy
OncologyPharmacology
2009English

The Value of Trabectedin in the Treatment of Soft Tissue Sarcoma

Therapeutics and Clinical Risk Management
2016English

Efficacy of Trabectedin in Advanced Soft Tissue Sarcoma: Beyond Lipo- And Leiomyosarcoma

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Trabectedin for Inoperable or Recurrent Soft Tissue Sarcoma in Adult Patients: A Retrospective Cohort Study

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Clinical Evaluation for Locally Recurrent Soft Tissue Sarcoma.

Orthopedics & Traumatology
1995English

Immunotherapy in Soft-Tissue Sarcoma

Current Oncology
Oncology
2020English

Clinical and Radiologic Features Together Better Predict Lung Nodule Malignancy in Patients With Soft-Tissue Sarcoma

Journal of Clinical Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy